Pharma BD Deal Intelligence

Bain Capital Private Equity / Cinven Partners (Nidda Healthcare Holding AG) / STADA Arzneimittel AG

2017 · Take-Private · $6.1B · Complete

Bain Capital and Cinven (Nidda Healthcare Holding AG) successfully completed a renewed voluntary public takeover of STADA at EUR 66.25/share (EUR 65.53 + EUR 0.72 dividend), valuing the German generics/biosimilars/branded OTC company at approximately EUR 5.3B (~$6.1B). 63.85% of shares tendered. The PE owners later transformed STADA into a global generics/specialty platform.

Did it work? Outcome assessment

Assessment window: 5yr post-close.

Key facts

• Announced Aug 18, 2017
• Closed Aug 18, 2017
• Deal value $6.1B
• Deal type Take-Private
• Therapeutic area Multiple (generics, branded specialty, biosimilars)
• Indications Multiple (generics, branded specialty, biosimilars)
• Key assets Generic and OTC pharmaceutical portfolio (incl. biosimilars)
• Mechanism Generic and branded pharmaceutical product platform

← Browse all deals  ·  How we score deals